2Janka HU,Plewe G,Riddle MC,et al. Comparison of basal insu lin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care, 2005,28: 254 259.
3Rosenstock J, Dailey G, Massi-Benedetti M, et al. Reduced hy poglycemia risk with insulin glargine : a meta - analysis compa ring insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care, 2005,28 : 950-955.
5The diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIT) study reseach group.Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes[J].N Engl J Med,2005,353:2643-2653.
6Riddle Mc,Rosenstock J,Gerich Jet al.The treat-to-target trail:Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients[J].Diabetes Care,2003,26:3080-3086.
7Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes ; a comsemsus algorithm for the ini- tiation and adjustment of therapy; a consensus statement of the A- merican Diabetes Association and the European Association for the study of Diabetes[J]. Diabetes Care. 2009.32( 1), 193-203.
8Rosenstock J, Daitey G, Massi-Benedetti M, et al. Reduced hypo- glycemia risk with insulin glargine: a meta-analysis comparing insu- lin glargine with human NPH insulin in type 2 diabetes[ J]. Diabe- tes Care, 2005,28 (3) :950-955.
9Stratton IM,Adler AI,Neil HA,et al. Association of glycaemia with_ macrovascular and microvascular complications of type 2 diabetes ( UKPDS35 ) : prospective observational study [J].BMJ, 2000,321 (7258) : 405-412.
10ADA. Standards of medical care for patients with diabetes mellitus[J]. Diabetes Care,2003,26(Suppl 1) :S33-S50.
